Barry Borlaug

Professor

Mayo Clinic

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Barry Borlaug is a Professor at Mayo Clinic in the United States. His research primarily focuses on heart failure with preserved ejection fraction (HFpEF), exercise hemodynamics, and the clinical implications of various heart conditions. His recent articles explore the effects of myeloperoxidase inhibition, exercise echocardiography, and the prognostic value of diuretic dosages in heart failure patients.

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (8)

Rickey Carter

Professor, Biostatistics

Mayo Clinic

UNITED STATES

View details

Kenneth Margulies

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES

View details

Mansoor Husain

CANADA

View details

Niels Møller

Aarhus University Hospital

DENMARK

View details

Patricia A Pellikka

UNITED STATES

View details

Masaru Obokata

Gunma University Graduate School of Medicine

UNITED STATES

View details

Darren McGuire

Distinguished Teaching Professor

University of Texas Southwestern Medical School

UNITED STATES

View details

Sorin V Pislaru

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Barry Borlaug

Research Interests

Explore related searches

Contact this professor

About

Articles (30)

Acute Effects of Myeloperoxidase Inhibition on Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial

Feasibility, Reproducibility, and Prognostic Value of Exercise Echocardiography for Cardiac Output Reserve Assessment in Fontan Physiology

Limited Ventilatory Reserve During Exercise in Heart Failure with Preserved Ejection Fraction

Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial

HFpEF-ABA score is a more useful enrichment tool than natriuretic peptides in heart failure with preserved ejection fraction

Association of Diuretic Dosage With Outcomes in Patients With Hemodynamically Significant Isolated Tricuspid Valve Regurgitation

Physiologic Phenotyping of Responses to Exercise and Activity in Heart Failure

Atrioventricular Dyssynchrony and Dyspnea in Heart Failure With Preserved Ejection Fraction

Clinical Outcomes of Mitral Regurgitation Severity and Transcatheter Edge‐to‐Edge Repair in Atrial Functional Mitral Regurgitation

Pulmonary arterial wedge pressure exceeding left atrial pressure: clinical implications

Pathophysiological insights into HFpEF from studies of human cardiac tissue

Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials

Response by Kosiborod et al to Letter Regarding Article, “Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial”

Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction

Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

Obesity and Heart Failure: A New Era Begins

Racial Differences of Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction

Imaging and mechanisms of heart failure with preserved ejection fraction: a state-of-the-art review

Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction

Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind Trial

Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Prevalence and Incidence of Diastolic Dysfunction in Atrial Fibrillation: Clinical Implications

SGLT2 inhibitors and diuretics in heart failure: clicking reset on the renal volume setpoint?

Daytime Versus Nighttime Ambulatory Blood Pressure Monitoring in Coarctation of Aorta

Obesity, Cardiorenal Comorbidities, and Risk of Hospitalization in Patients With Heart Failure With Preserved Ejection Fraction

Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials

Histologic and proteomic remodeling of the pulmonary veins and arteries in a porcine model of chronic pulmonary venous hypertension

Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets

Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions

Collaborators (8)

Rickey Carter

Kenneth Margulies

Mansoor Husain

Niels Møller

Patricia A Pellikka

Masaru Obokata

Darren McGuire

Sorin V Pislaru

Make your next move.